The Amazing “Cell Therapy” – A New Direction in Immune ...

Less is more for health and happiness

The Amazing “Cell Therapy” – A New Direction in Immune Tolerance Induction

· science,art,clinical trials,treatment

That day, the harbor welcomed a special guest—Dr. Georg Schett, a famous immunologist. He brought the latest immune tolerance induction technology to the harbor, helping residents with autoimmune diseases. Popeye, Olive Oyl, and Bluto went to Dr. Schett’s temporary lab specially, eager to see this amazing new technology.

In the lab, all kinds of precision instruments were lined up neatly, glowing softly. Scientists in white coats were busy operating the equipment. Bluto leaned forward curiously, staring at the cell culture dishes on the clean bench. He whispered, “Popeye, what are these cells for? They look amazing.”

Episode 8: The Amazing “Cell Therapy” – A New Direction in Immune Tolerance Induction That day, the harbor welcomed a special guest—Dr. Georg Schett, a famous immunologist. He brought the latest immune tolerance induction technology to the harbor, helping residents with autoimmune diseases. Popeye, Olive Oyl, and Bluto went to Dr. Schett’s temporary lab specially, eager to see this amazing new technology. In the lab, all kinds of precision instruments were lined up neatly, glowing softly. Scientists in white coats were busy operating the equipment. Bluto leaned forward curiously, staring at the cell culture dishes on the clean bench. He whispered, “Popeye, what are these cells for? They look amazing.” Dr. Schett walked over with a smile, patting Bluto’s shoulder. “Kid, you’ve got a great sense of curiosity. We’re nurturing and strengthening immune cells, developing our latest treatment—cell therapy.” “Cell therapy?” Olive Oyl asked, curious. “Dr. Schett, how is this different from the immune tolerance induction therapy we talked about before?” Dr. Schett smiled, explaining: “The immune tolerance induction therapy we talked about earlier uses antigen delivery to let the patient’s own immune cells ‘learn’ to recognize their own people. Cell therapy, on the other hand, takes healthy immune cells—like regulatory T cells—directly from the patient’s body. We culture and strengthen them in the lab, making them stronger and more precise, then infuse them back into the patient’s body to work directly. It’s more direct and efficient than traditional antigen delivery.” Popeye nodded, adding: “It’s like picking the bravest, most capable patrolmen from the harbor, training them hard in a camp to make them stronger, then sending them back to their posts to guard the harbor. Cell therapy picks the best Treg cells from the patient’s body, strengthens their abilities, so they can control those confused immune patrolmen better and build immune tolerance quickly.” “How exactly does this therapy work?” Bluto asked. Dr. Schett took them to another instrument, pointing to the cell sample inside: “First, we take a small amount of Treg cells from the patient’s blood—like fishing a few small fish from the sea. Then, in the lab, we provide these Treg cells with plenty of nutrients to make them multiply quickly. At the same time, we train them intensively, so they can recognize their own antigens precisely and suppress the ‘rebellious’ immune cells. Finally, we infuse these strengthened Treg cells back into the patient’s body through an IV, letting them start working immediately to help the patient rebuild immune tolerance.” “Are there other cell therapies besides Treg cell therapy?” Olive Oyl asked. Dr. Schett nodded: “Of course. There’s also dendritic cell therapy. Dendritic cells are the ‘trainers’ of the immune patrol. We modify dendritic cells to present their own antigens better, inducing T cells to build tolerance, thus achieving the therapeutic effect.” Bluto’s eyes lit up: “This therapy is so amazing! Can everyone with autoimmune diseases use it?” Dr. Schett shook his head: “Currently, cell therapy is mainly used for patients with more severe autoimmune diseases—like those who don’t respond well to traditional treatments. This therapy is still being improved. In the future, we’ll make it safer and more popular, helping more people get rid of the illness.” Popeye patted Bluto’s shoulder: “Science is always advancing, just like we’re always working to make the harbor safer. Next episode, we’ll look at the advantages and disadvantages of this amazing immune tolerance induction therapy, helping everyone understand it more comprehensively.”

Dr. Schett walked over with a smile, patting Bluto’s shoulder. “Kid, you’ve got a great sense of curiosity. We’re nurturing and strengthening immune cells, developing our latest treatment—cell therapy.” “Cell therapy?” Olive Oyl asked, curious. “Dr. Schett, how is this different from the immune tolerance induction therapy we talked about before?”

Dr. Schett smiled, explaining: “The immune tolerance induction therapy we talked about earlier uses antigen delivery to let the patient’s own immune cells ‘learn’ to recognize their own people. Cell therapy, on the other hand, takes healthy immune cells—like regulatory T cells—directly from the patient’s body. We culture and strengthen them in the lab, making them stronger and more precise, then infuse them back into the patient’s body to work directly. It’s more direct and efficient than traditional antigen delivery.”

Popeye nodded, adding: “It’s like picking the bravest, most capable patrolmen from the harbor, training them hard in a camp to make them stronger, then sending them back to their posts to guard the harbor. Cell therapy picks the best Treg cells from the patient’s body, strengthens their abilities, so they can control those confused immune patrolmen better and build immune tolerance quickly.”

“How exactly does this therapy work?” Bluto asked. Dr. Schett took them to another instrument, pointing to the cell sample inside: “First, we take a small amount of Treg cells from the patient’s blood—like fishing a few small fish from the sea. Then, in the lab, we provide these Treg cells with plenty of nutrients to make them multiply quickly. At the same time, we train them intensively, so they can recognize their own antigens precisely and suppress the ‘rebellious’ immune cells. Finally, we infuse these strengthened Treg cells back into the patient’s body through an IV, letting them start working immediately to help the patient rebuild immune tolerance.”

“Are there other cell therapies besides Treg cell therapy?” Olive Oyl asked. Dr. Schett nodded: “Of course. There’s also dendritic cell therapy. Dendritic cells are the ‘trainers’ of the immune patrol. We modify dendritic cells to present their own antigens better, inducing T cells to build tolerance, thus achieving the therapeutic effect.”

Bluto’s eyes lit up: “This therapy is so amazing! Can everyone with autoimmune diseases use it?” Dr. Schett shook his head: “Currently, cell therapy is mainly used for patients with more severe autoimmune diseases—like those who don’t respond well to traditional treatments. This therapy is still being improved. In the future, we’ll make it safer and more popular, helping more people get rid of the illness.”

Popeye patted Bluto’s shoulder: “Science is always advancing, just like we’re always working to make the harbor safer. Next episode, we’ll look at the advantages and disadvantages of this amazing immune tolerance induction therapy, helping everyone understand it more comprehensively.”

Science behind

Adoptive Immune Cell Therapy Using Autologous CAR-T Cells for Autoimmune Diseases

(A) We can use CAR-T cells specifically targeting B cell markers (such as CD19) to eliminate the "bad B cells" that attack the body's own tissues, thereby achieving broad-scale clearance of pathogenic B cells. (B) To make this elimination more precise and avoid "killing innocent cells," scientists have developed a precision targeting technology that specifically targets only those particular pathogenic B cells that produce autoantibodies and truly cause disease. This technology is called CAAR-T cells (Chimeric Autoantibody Receptor T cells). (C) In addition to directly eliminating "bad cells," there's another approach: instead of killing them, we make them behave and quiet down. This involves using CAR-modified regulatory T cells (Tregs) to suppress abnormal immune activity. Blache U, Tretbar S, Koehl U, Mougiakakos D, Fricke S. CAR T cells for treating autoimmune diseases. RMD Open. 2023;9:e002907. https://doi.org/10.1136/rmdopen-2022-002907

(A) We can use CAR-T cells specifically targeting B cell markers (such as CD19) to eliminate the "bad B cells" that attack the body's own tissues, thereby achieving broad-scale clearance of pathogenic B cells.

(B) To make this elimination more precise and avoid "killing innocent cells," scientists have developed a precision targeting technology that specifically targets only those particular pathogenic B cells that produce autoantibodies and truly cause disease. This technology is called CAAR-T cells (Chimeric Autoantibody Receptor T cells).

(C) In addition to directly eliminating "bad cells," there's another approach: instead of killing them, we make them behave and quiet down. This involves using CAR-modified regulatory T cells (Tregs) to suppress abnormal immune activity.

Blache U, Tretbar S, Koehl U, Mougiakakos D, Fricke S. CAR T cells for treating autoimmune diseases. RMD Open. 2023;9:e002907. https://doi.org/10.1136/rmdopen-2022-002907